Valuation
- Market cap
- 89,004,000
- Revenue TTM
- $860,000
- Net income TTM
- $-8,980,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- -1,044.19%
- Debt to equity
- 0.00
Trading
- Volume
- 7,800
- Avg volume
- 15,072
- Day's range
- $16.69 – $17.22
- Shares out
- 5,311,000
- Stochastic %K
- 77%
- Beta
- -0.72
- Analysts
- Hold
- Price target
- $8.00
Company profile
Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the tre...
Show more
Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. The company has a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases, as well as collaboration agreement with Johnson & Johnson to provide therapeutic solutions for pregnant individuals at risk of fetal and neonatal alloimmune thrombocytopenia. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 203 859 3820
- Website
- https://www.rallybio.com
- Address
- 234 Church Street, New Haven, United States
Latest news
No headlines yet.
